TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean ADC value of malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of ADC value for malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of ADC value for malignant lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean gastric half emptying time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: F2-Isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ureteral access sheath use
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients requiring oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to eye closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in vaginal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived hygiene of medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: C-TTO responses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Agreement with the new mandatory policy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response rates on the Short Posttraumatic Stress Disorder Rating Interview Global Improvement measure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores on the Structured Interview for Posttraumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores on the Hospital Anxiety Depression Scale anxiety subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Excessive gestational weight gain (GWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gestational diabetes mellitus diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with near and intermediate visual outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Distance-corrected intermediate visual acuity at 90 cm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urinary urgency and frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: improvement in upper arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with uncorrected visual acuity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: circulating IFN-gamma positive CD4+ lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: duration of treatment before withdrawal from the trial
Endpoint domain: Mortality/survival
Primary endpoint: Upper limb strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events of grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-free survival hazard ratio
Endpoint domain: Mortality/survival
Primary endpoint: subjective pain VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative liver dysfunction score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and biliary outcomes
Primary endpoint: Liver glycogen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean maximal decrease in HCV RNA log(10) (IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: admissions to hospital for heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of discharge
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: isometric muscle strength of the biceps brachii
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: isometric muscle strength of the triceps brachii
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total scores of COPM
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Leg muscle soreness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ease of pedaling
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of secondary fragility fracture
Endpoint domain: Mortality/survival
Primary endpoint: Levels of sICAM‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of sVCAM‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Survival difference between treatment groups
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in atherogenic lipid profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Use of emergency help
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in leptin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in TNF‐α concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Platelet aggregation induced by ADP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate recovery at one minute after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of ethanol in kombucha products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital days at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: symptom reductions at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in quality of life at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Risk of maternal-infant HIV transmission
Endpoint domain: Mortality/survival
Primary endpoint: Pain and function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Catastrophizing scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: less severe symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher recovery scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: less likely to be depressed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in mean daily frequency of micturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hands-off-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of correct chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak oxygen uptake (VO(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with a skeletal-related event (SRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean skeletal morbidity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to progression of bone lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baroreflex responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total work done above CP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time maintained at V˙O2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NO production in platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in QTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to onset of sensory block at S1 and S3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency and duration of headache attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality-of-life parameters
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bone level alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean change in NRS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in nephrotic‐range proteinuria to subnephrotic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: peak postoperative cTnI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean visual analog scale pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean verbal rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC pit levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: calcium self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of chamber and VA origin identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of radiofrequency-energy applications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: X-ray radiation exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Enamel Hardness (HD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six-minute walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Barthel Index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak uroflow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients requiring no further treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean apoptotic index of lamina propria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean apoptotic index of myofibroblast cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Availability of naloxone for same-day purchase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: balloon insertion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: decreased anemia at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: decreased parasitological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement on CGI improvement scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Beneficial clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SKAMP-combined score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime actigraph-measured activity counts per epoch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total actigraph-measured activity counts accrued throughout the entire waking period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: television viewing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematoma development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain improvement measured by WOMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function improvement measured by SF-36
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Car seat use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pre-hospital delay time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of atomoxetine formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste acceptability of oral solution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neutral ankle position during walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutral ankle position during jogging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coordinative concentric and eccentric deviation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant pain relief (>/= 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in ODI (by at least 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in low-density lipoprotein (LDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in high-density lipoprotein (HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intake of alpha-linolenic acid (alpha-LA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: remission at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: incidence of relapses
Endpoint domain: Adverse events/effects
Primary endpoint: respiratory tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: Full-thickness macular hole closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cancelled cycles
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of embryo transfers
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of menstrual irregularities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Survival (OS) ≥24 months
Endpoint domain: Mortality/survival
Primary endpoint: Risk of rapid progression of axial elongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability (relBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective rating scales for self-confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Repeat exposures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: performance on standard neuropsychological tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: tentative diagnosis agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity for subgroup classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tympanogram results improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of patients with normal hearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: papilla height preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recession changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of infective complication
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of cycles with perfect use of the patch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average area under the plasma concentration‐time curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption rate constant (ka)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and grade of ARIE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of ARIE occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of ARIE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lopinavir trough concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent over BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: z-BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parent BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-frequency power of systolic arterial pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transfer function gain in the high-frequency range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days of HF hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First HF rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Combined endpoint of death or HF rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: time to maximum activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: time from maximum activity to half activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: mean transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: LVM (Left Ventricular Mass)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CMVR (Coronary Microvascular Resistance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EAT volume (Epicardial Adipose Tissue volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24 h IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 24 h trough IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 24 h IOP fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 30-day multiple point prevalence abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day single point prevalence abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of speech in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective measures of benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Re-infarction rates
Endpoint domain: Mortality/survival
Primary endpoint: LVEF value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Cytokine levels in amniotic fluid and maternal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Plasma oxymorphone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychomotor effects of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective drug effects of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal lumen cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily bodyweight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moxifloxacin aqueous and vitreous levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum inhibitory concentration for 90% of isolates (MIC(90))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FVCEX (Forced Vital Capacity Exhaled)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cytokine receptor expression (IL-4R, IL-5R, IFN-gammaR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in pigment in pigmentary lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peak pressure gradient across the aortic valve prostheses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postprocedure fear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knowledge mean score improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of exercises performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in TUG and BBS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes